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Abstract:Background: The effects of glucose–insulin–potassium in the treatment of ST segment elevation 
myocardial infarction are controversial. We aimed to evaluate the effect of this solution on ST segment resolution 
which is an early noninvasive marker of coronary reperfusion. Methods: From September 2008 to July 2009, this 
randomized clinical trial enrolled 74 patients who had myocardial infarction that was treated with 25% glucose, 50 
unit of soluble insulin per liter, and 80 mille mol of potassium chloride per liter at 1 ml/kg/hour (case group) or 
normal saline (control group) as adjunct to thrombolytic therapy in Sabzevar ,Iran . ST-segment resolution was 
defined as complete (>70%), partial (30% to 70%), or none (<30%) and absent (<50%) or present (≥50%).  Results: 
No difference was present between groups in ST-segment resolution (p=0.8).  There was no difference in the rate of 
complete ST-segment resolution between groups at 120 min (P=NS).Left ventricular ejection fraction was 
significantly higher in patients who had complete ST-segment elevation resolution (44.6± 7.4%) than others (40.9± 
9.2 %and 35.0± 9.2%). Conclusion: ST-segment resolution was similar in groups. A more degree of ST-segment 
elevation resolution was correlated with better ejection fraction. 
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1. Introduction 
The ST-segment resolution on 
electrocardiogram (ECG) has been shown to be a 
simple, indicator of reperfusion (1) (2) (3) (4), which 
is the most effective treatment in acute myocardial 
infarction(5).However, reperfusion itself may cause 
reperfusion myocardial injury and affect infarct size. 
Therefore, next step is limiting myocardial infarct size 
in order to improve clinical outcomes in patients with 
myocardial infarction(6). One of these strategies is 
treatment with glucose–insulin–potassium (GIK) 
which can shift myocardial free fatty acid metabolism 
towards glucose metabolism(7) , but the effects of 
glucose–insulin–potassium in the treatment of ST 
segment elevation myocardial infarction (STEMI) are 
controversial. Fath-Ordoubadi et al published a meta-
analysis of GIK treatment and showed that GIK 
infusion could reduce in-hospital mortality (8), while 
in some studies, no benefit effects of GIK were 
observed(9) (10) (11). 
However, studies about GIK effects are 
ongoing; the effects on ST-segment resolution have 
been used in a few studies. Hence we investigated the 
effect of administration of GIK on single-lead ST-
segment analysis before and 120 minutes after 
thrombolytic therapy. In addition we used a different 
thrombolytic in this study (streptokinase) which is not 
investigated in previous studies. 
 
2. Materials and Methods 
This is a part of a study which evaluated the 
effects of GIK on STEMI.As soon as the university 
ethic committee approved the research, recruitment 
began. From September 2008 to July 2009, 74 
consecutive STEMI patients were randomized to 
normal saline (N = 39) or GIK infusion (N = 35).two 
ECGs in the GIK group were not valid to include in 
the study. All consecutive patients who had ST 
elevation myocardial infarction according to AHA 
guildline, when admitted to the Coronary Care Unit of 
the vaseie general hospital (Sabzevar ,Iran) were 
recruited (12) (13). Details of study design and 
population are described elsewhere(14) 
Patient with hypotension, congestive heart 
failure, creatinine >2.0 mg/dL and anemia 
(hemoglobin <11 g/dL), were excluded. Further 
exclusion criteria were unwillingness to participate. 
Informed consent was obtained from the participants 
or their legal guardians.  
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The study was randomized, prospective, and 
triple blinded. On admission, patients were 
randomized via block randomization and assigned to 
the respective group by a closed envelope system. In A 
group, patients received high-dose GIK infusion (25% 
glucose, 50 IU of soluble insulin per liter, and 80 
mmol of potassium chloride per liter at 1 ml/kg/hour) 
as an adjunct to thrombolytic therapy (1.5 MU of 
streptokinase/30 to 60 minutes) [GIK group].In B 
group 1 L normal saline at 60 mL/h infused in addition 
to thrombolytic therapy (1.5 MU of streptokinase/30 to 
60 minutes) [control group]. Neither the patients nor 
the researcher and investigator assessing the ECGs, 
nor the statistical consultant knew which group called 
A and which one called B group (triple blinded). GIK 
administered in the hospital that initiated the 
reperfusion therapy. All other medication was standard 
as ACC/AHA guidelines. (13)  
In each patient, total CK and CK-MB level 
were measured on admission, 16 and 24 hours 
thereafter. In all patients, plasma concentrations of 
glucose and potassium were determined before and at 
6 hour after administering therapy. Two-dimensional 
echocardiography was obtained in all patients after 72 
hours of admission. 
A standard 12-lead electrocardiogram with a 
speed of 25 mm/s and amplitude of 10 mm/mV were 
obtained before and within 120 minutes of starting 
treatment .ST-segment elevation was investigated by a 
single observer who was blinded to study groups with 
lens-intensified calipers. The single lead with the most 
prominent ST-segment elevation before treatment was 
identified, and ST-segment elevation was measured at 
20 ms after the J point with the PR segment as 
reference baseline. The percent resolution of ST-
segment deviation from baseline to 120 was calculated 
and categorized: complete (>70%) STRs, partial (30% 
to 70%) STRs, and no (<30%) STRes [5].Another 
classification was performed as present ST-segment 
resolution (STRes ≥50%) or absent ST-segment 
resolution (STRs <50%). A similar approach was used 
in recent studies (15) (16) (17).  Patients were 
followed clinically for 7 days.  
Data were analyzed thorough the Statistical 
Package for the Social Sciences (SPSS, version15). 
Continuous variables were expressed as mean ± SD 
and were compared using independent t tests and 
repeated measure ANOVA. Categorical data were 
analyzed by use of chi-square or Fisher exact test. The 
relation between ST segment resolution and left 
ventricular ejection fraction was made with 2-way 
analysis of variance. Assuming a power of 80% and 
α=5%, comparing ST segment resolution could be 
demonstrated with a sample size of 32 patients in each 
group. A p value <0.05 was considered to be 
statistically significant. 
4. Results 
74 Patients were enrolled into the study. 
There was no significant difference in basal data 
between two study groups.The time from chest pain 
onset to initiation of streptokinase was 4.66±3.81 
hours. There was no significant difference in this 
interval between two study groups (P=0.16). Glucose 
level at Baseline was 149±61 mg/dL in the control and   
168±83 mg/dL in the GIK group (P=0.25). Mean 
glucose level over 6 hours was higher in the GIK 
group (212± 139 mg/dL) than control group (142±46 
mg/dL) (P=0.006).  
No difference was present between two 
groups in ST-segment elevation resolution (p=0.8). 
Ejection Fraction (39% G vs41% C, p=0.34) was 
similar between the two groups.  
In GIK and control group, complete 
resolution was registered in 8 patients (25%) vs 18 
patients(46.2%), partial in 12 (37.5%) vs 14(35.9%), 
and absent in 12 (37.5%) vs 7(17.9%) , 
respectively(P=NS).A resolution ≥50% was observed 
in 56.3% of patients in GIK group, and in 71.8 % of 
control group (P=0.17).  
Left ventricular EF was significantly higher 
in patients who had complete ST-segment elevation 
resolution (44.6± 7.4%) than in those who had partial 
resolution (40.9± 9.2 %,), and in patients who had 
absent resolution (35.0± 9.2%), (p=0.003).  
There was no significant difference between groups 
regarding mean admission serum CK, peak CK, peak 
CK-MB levels and early peak of CK within 16 hour.  
 
3. Discussion:    
According to our data GIK therapy in patients 
who receive streptokinase ,offers no effect on ST-
segment resolution, which is a sign of successful 
recanalization (18). 
The simplest approach to analyze ST-segment 
resolution is to classify ST-segment elevation in 
different groups and to categorize the patient in these 
groups. One of these classifications is ST-segment 
resolution with the 50% cutoff as present or absent 
(15) (16) (19). We also used the other common 
classification with 70% and 30% thresholds, as 
complete, partial, or absent ST-segment elevation 
resolution, (20) .We found GIK ineffective according 
to both classification. 
   Previous studies have investigated the effect 
of GIK on ST-segment elevation resolution in animals. 
GIK has decreased ST-segment elevation in dogs with 
induced myocardial ischemia (21). Result of 
differences between animal studies versus our study 
can be due to thinner myocardium in animals which is 
more resistant to ischemia after myocardial infarction 
than in humans with thick myocardium.  One study 
showed that GIK can decrease in free fatty acid 
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concentration and promotion of glycolysis. Therefore 
an ischemic cell needs less oxygen and produces less 
toxic intermediates of free fatty acid metabolism  (7). 
However, while reperfusion therapy with streptokinase 
can rescue the ischemic myocardium effectively, 
treatment with GIK has less value. In a post hoc 
analysis, GIK results in a higher number of patients 
with partial or complete ST-segment elevation 
resolution but they suggested more prospective trial 
(22). In 32 ST-elevation MI patients treated with 
reteplase and alternately assigned to either GIK or 
saline with potassium chloride, GIK failed to decrease 
ST-segment elevation (23), which is corresponding to 
our study with enough sampling. Therefore at least at 
the present time, there is no role for GIK as adjunctive 
treatment with thrombolytic drugs. 
In our study, ST-segment elevation resolution 
was related to a favorable outcome in EF according to 
both classification of ST segment resolution, which is 
corresponding to previous studies (15) (24) (25). We 
suggest the use of electrocardiogram to estimate left 
ventricular function. Or, in minimum ST-segment 
evaluation can be used to categorize outcome as 
acceptable or unacceptable. 
We should mention some limitations of this 
study. We used easy-to-use method to analyze ST-
segment resolution and using all ECG leads could 
have produced different results. However, this method 
has been used and validated in previous studies. (16) 
(26) (27) (28) And, recent studies failed to 
demonstrate advantages of more complex 
measurements. (26) (27).However, one of  the 
advantages of this method is early decision making 
because we can evaluate it shortly after treatment. As 
far as there is no data about functional status before 
infarction, we could not recognize functional recovery, 
and we cannot exclude some degree of functional 
impairment in a patient with normal left ventricular 
EF. 
   In conclusion, in patients with STEMI, 
according to ECG finding, there is no role for GIK as 
adjunctive treatment with streptokinase, but a more 
degree of ST-segment elevation resolution remains a 
valuable predictor of effective reperfusion and left 
ventricular EF.  
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